Antihypertensives for kidney transplant recipients: Systematic review and meta-analysis of randomized controlled trials

Transplantation

Volumn 88, Issue 1, 2009, Pages 7-18

  Cross, Nicholas B ^a,b   Webster, Angela C ^a,b,c   Masson, Philip ^d   O'Connell, Philip J ^c   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Antihypertensive agents; Kidney transplantation; Meta analysis; Review

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; GALLOPAMIL; GUANFACINE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; ISRADIPINE; LABETALOL; LACIDIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PINACIDIL; TERTATOLOL; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD PRESSURE; GRAFT SURVIVAL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 67651012067     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a9e960     Document Type: Review

References (100)

1. Kasiske B, Chakkera HA, Roel J. Explained and unexplained ischaemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
2. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
3. El-Agroudy AE, Bakr MA, Shehab El-Dein AB, et al. Death with functioning graft in living donor kidney transplantation: Analysis of risk factors. Am J Nephrol 2003; 23: 186.
4. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217.
5. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(suppl 15): S1.
6. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
7. Barama AA. Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008; 68(suppl 1): 33.
8. Kendrick E. Cardiovascular disease and the renal transplant recipient. Am J Kidney Dis 2001; 38: S36.
9. Curtis JJ. Treatment of hypertension in renal allograft patients: Does drug selection make a difference? [review, 22 refs]. Kidney Int Suppl 1997; 63: S75.
10. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. Br Med J 2004; 329: 828.
11. Nicholls K. Kidney Health Australia and the Australian and New Zealand Society of Nephrology. CARI guidelines for prevention of progression of chronic renal failure. ACE inhibitor treatment in diabetic nephropathy. Nephrology 2006; 11(suppl 1): S79.
12. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(suppl 1): 1.
13. Baroletti SA, Gabardi S, Magee CC, et al. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: Fact or fiction [review, 68 refs]. Pharmacotherapy 2003; 23: 788.
14. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. Cochrane Database of Systematic Reviews 2009; 3.
15. Higgins JPT, Green S, eds. Cochrane Handbook for systematic reviews of interventions, vol. 5.0.0. Copenhagen, Denmark: The Cochrane Collaboration; 2008.
16. DerSimonian R, Laird M. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177.
17. 9.4.5.2 Meta-analysis of change scores. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, vol. 5.0.0. Copenhagen, Denmark: The Cochrane Collaboration; 2008.
18. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559.
19. Cartier F, Merot ML. [Effect of sustained release alprenolol in hypertension uncontrolled by chlorothiazide and dihydralazine. Study in double blind (author's transl)]. Sem Hop 1978; 54: 855 (in French).
20. Riggio R, Haschemeyer R, Cheigh J, et al. Does enalapril retard the progression of renal insufficiency in kidney transplant recipients? [abstract]. J Am Soc Nephrol 1992; 3: 877.
21. Philipp T, Legendre C, Geiger H, et al. Study on the evaluation of candesartan cilexetil after renal transplantation (SECRET study) [abstract, no: P04.09]. Kidney Blood Press Res 2004; 27: 331.
22. Calo L, Giacon B, Davis PA, et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin Nephrol 2002; 58: 103.
23. Aros CA, Ardiles LG, Schneider HO, et al. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Transplant Proc 2005; 37: 3364.
24. Almeshari K, Alshaibani K, Alfurayh O, et al. The antihypertensive and renal protective effects of amlodipine versus cilazapril in renal transplant recipients with hypertension [abstract]. Nephrol Dial Transplant 2000; 15: A70.
25. Sennesael J, Lamote J, Violet I, et al. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995; 26: 436.
26. Guerin C, Berthoux P, Broyet C, et al. [Effects of diltiazem on arterial pressure and renal function in renal transplanted and cyclosporin A treated subjects. Results after 3 months of a prospective study]. Arch Mal Coeur Vaiss 1989; 82: 1223 (in French).
27. Harper SJ, Moorhouse J, Abrams K, et al. The beneficial effects of oral nifedipine on cyclosporin-treated renal transplant recipients - A randomised prospective study. Transpl Int 1996; 9: 115.
28. Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial. Lancet 1999; 354: 1415.
29. Venkat-Raman G, Feehally J, Coates RA, et al. Renal effects of amlodipine in normotensive renal transplant recipients. Nephrol Dial Transplant 1999; 14: 384.
30. Wilkie ME, Beer JC, Evans SJ, et al. A double-blind, randomized, placebo-controlled study of nifedipine on early renal allograft function. Nephrol Dial Transplant 1994; 9: 800.
31. Wilkie ME, Beer JC, Raftery MJ, et al. Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients. Transplant Proc 1993; 25 (1 part 1): 612.
32. Madsen JK, Sorensen SS, Hansen HE, et al. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998; 13: 2327.
33. van der Schaaf MR, Hene RJ, Floor M, et al. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77.
34. Beckingham IJ, Woodrow G, Hinwood M, et al. A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant 1995; 10: 2316.
35. Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000; 58: 889.
36. Kim IG, Bagdasaryan AR, Birukova LS, et al. The effect of enalapril on the progression of chronic allograft nephropathy [abstract]. Nephrol Dial Transplant 2002; 17(suppl 1): 324.
37. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Ren Fail 2003; 25: 77.
38. Gronhagen-Riska C, Fyhrquist F, Ahonen J, et al. Angiotensin I-converting enzyme inhibition after renal transplantation. Scand J Urol Nephrol Suppl 1984; 79: 63.
39. Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: A randomized clinical trial. Am J Kidney Dis 2007; 50: 133.
40. Rashtchizadeh N, Aghaeishahsavari M, Argani H, et al. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Clin Biochem 2007; 40: 194.
41. Takahara S, Moriyama T, Kokado Y, et al. Randomized prospective study of effects of benazepril in renal transplantation: An analysis of safety and efficacy. Clin Exp Nephrol 2002; 6: 242.
42. Alcaraz A, Oppenheimer F, Talbot-Wright R, et al. Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplant Proc 1991; 23: 2383.
43. Campistol JM, Oppenheimer F, Vilardell J, et al. Interaction between ciclosporin and diltiazem in renal transplant patients. Nephron 1991; 57: 241.
44. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300.
45. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 1991; 2: 983.
46. Frei U, Harms A, Bakovic-Alt R, et al. Calcium channel blockers for kidney protection. J Cardiovasc Pharmacol 1990; 16(suppl 6): S11.
47. Morales JM, Rodriguez-Paternina E, Araque A, et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: A 5-year prospective randomized study. Transplant Proc 1994; 26: 2598.
48. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889.
49. Rump LC, Oberhauser V, Schwertfeger E, et al. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens 2000; 18: 1115.
50. Santos AF, Keitel E, Bittar A, et al. Long term results of diltiazem use associated to cyclosporin in renal transplantation [abstract]. Presented at XIXth International Congress of the Transplantation Society, Miami, FL, Aug 25-30, 2002.
51. Sperschneider H, Wagner C, Korn A, et al. [. Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].. Med Klin 1997; 92: 589 (in German).
52. Wagner K, Albrecht S, Neumayer HH. [Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study]. Dtsch Med Wochenschr 1986; 111: 1363 (in German).
53. Wahlberg J, Hanas E, Bergstrom C, et al. Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients. Transplant Proc 1992; 24: 311.
54. Gossmann J, Mondorf U, Dietz A, et al. A randomized prospective double-blind placebo-controlled study of gallopamil, calcium antagonist of the verapamil type, in stable cyclosporine-treated renal transplant recipients. Transplant Proc 2002; 34: 1767.
55. Kumana CR, Tong MK, Li CS, et al. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. Br J Clin Pharmacol 2003; 56: 670.
56. Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204.
57. Ladefoged SD, Pedersen E, Hammer M, et al. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: A randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 543.
58. Lehtonen S, Isoniemi H, Salmela K. A randomised placebo controlled study on initial isradipine therapy in renal transplantation: Long-term results [abstract]. Nephrol Dial Transplant 2000; 15: A276.
59. Morales JM, Andres A, Prieto C, et al. Calcium antagonist treatment of recipients minimizes early cyclosporine nephrotoxicity in renal transplantation: A prospective randomized trial. Transplant Proc 1989; 21 (1 Part 2): 1537.
60. Pirsch JD, D'Alessandro AM, Roecker EB, et al. A controlled, doubleblind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. Am J Kidney Dis 1993; 21: 189.
61. van den Dorpel MA, Zietse R, Ijzermans JN, et al. Prophylactic isradipine treatment after kidney transplantation: A prospective double-blind placebo-controlled randomized trial. Transpl Int 1994; 7(suppl 1): S270.
62. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000; 70: 122.
63. Ok E, Akcicek F, Toz H, et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995; 59: 1623.
64. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787.
65. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43: 419.
66. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: A prospective randomized trial. Clin Transplant 2007; 21: 277.
67. Hernandez E, Morales JM, Andres A, et al. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplant Proc 1995; 27: 2239.
68. El Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300.
69. Page RL, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: Part IV: Drug-drug interactions. Circulation 2005; 111: 230.
70. Tacrolimus DRUGDEX® evaluation. MICROMEDEX® healthcare series. Gordon, Thompson Healthcare.
71. Ciclosporin DRUGDEX® evaluation. MICROMEDEX® healthcare series. Gordon, Thompson Healthcare.
72. Taal MW, Tomson C. Module 1: chronic kidney disease. UK Renal Association clinical practice guidelines. London: Royal College of Physicians of London and the Renal Association; 2007.
73. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
74. Lenihan CR, O'Kelly P, Mohan P, et al. MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Ren Fail 2008; 30: 345.
75. Chhabra D, Grafals M, Skaro AI, et al. Impact of anaemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008; 3: 1168.
76. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A metaanalysis of patient-level data. Ann Intern Med 2001; 135: 73.
77. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30.
78. Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind controlled trial. Lancet 2008; 372: 547.
79. Knoll GA, Cantarovitch M, Cole E, et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation - Study design. Nephrol Dial Transplant 2008; 23: 354.
80. Cruzado JM, Rico J, Grinyo JM, et al. The renin angiotensin system blockade in kidney transplantation: Pros and cons. Transpl Int 2008; 21: 304.
81. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. Br Med J 1999; 318: 1730.
82. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545.
83. Pharmaceutical benefits scheme: For health professionals. Department of Health and Aging, Australian Government. Available at: http://www.pbs.gov.au/ html/healthpro/home. Accessed 11 March 2009.
84. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350.
85. Altiparmak MR, Trablus S, Apaydin S, et al. Is losartan as effective as enalapril on posttransplant persistent proteinuria? Transplant Proc 2001; 33: 3368.
86. Celik A, Ok E, Unsal A, et al. Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis. Nephron 2000; 86: 394.
87. Schmidt A, Gruber U, Bohmig G, et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034.
88. Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: Prospective randomized study. Transplantation 2001; 72: 542.
89. Barenbrock M, Kosch M, Kobelt V, et al.Arandomised trial of effects of AT1-rezeptor- vs. calcium-channel-blockade on arterial function in hypertensive renal transplant recipients [abstract]. Dtsch Med Wochenschr 2001; 126: S193.
90. Formica RN, Friedman AL, Lorber MI, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006; 21: 1389.
91. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822.
92. Wei C, Lin R, Fink JC, et al. Reduced expression of angiotensin II and TGF-beta in renal biopsies of patients with chronic allograft nephropathy by candesartan [abstract]. J Am Soc Nephrol 2002; 13: 24a.
93. Barri YM, Ramos EL, Orig J, et al. Isradipine (isr) in the treatment of hypertension in renal transplant patients (rtp) on cyclosporin (csa): A randomized open-label cross-over study [abstract]. J Am Soc Nephrol 1995; 6: 1072.
94. Chanard J, Toupance O, Lavaud S, et al. Amlodipine reduces cyclosporininduced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003; 18: 2147.
95. Martinez-Castelao A, Hueso M, Sanz V, et al. Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immuno-suppression. Transplant Proc 2002; 34: 403.
96. Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862.
97. Weidanz JA, Jacobson LM, Muehrer RJ, et al. ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro. Kidney Int 2005; 67: 2134.
98. Andres A, Morales E, Morales JM, et al. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: A randomized multicenter study. Transplant Proc 2006; 38: 2419.
99. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Randomized placebocontrolled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation 2006; 81: 52.
100. Vanrenterghem Y, Waer M, De Keyser P, et al. Controlled trial of the protective effect of dihydroergotoxine (Hydergine) on cyclosporineassociated nephrotoxicity in renal graft recipients. Transplant Proc 1988; 20 (3 suppl 3): 615.